Creative Medical Technology Holdings Inc (CELZ) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Creative Medical Technology Holdings Inc stock (CELZ) is currently trading at $1.81. Creative Medical Technology Holdings Inc PS ratio (Price-to-Sales) is 1071.70. Analyst consensus price target for CELZ is $20.00. WallStSmart rates CELZ as Sell.
- CELZ PE ratio analysis and historical PE chart
- CELZ PS ratio (Price-to-Sales) history and trend
- CELZ intrinsic value — DCF, Graham Number, EPV models
- CELZ stock price prediction 2025 2026 2027 2028 2029 2030
- CELZ fair value vs current price
- CELZ insider transactions and insider buying
- Is CELZ undervalued or overvalued?
- Creative Medical Technology Holdings Inc financial analysis — revenue, earnings, cash flow
- CELZ Piotroski F-Score and Altman Z-Score
- CELZ analyst price target and Smart Rating
Creative Medical Technology Holdings Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Creative Medical Technology Holdings Inc (CELZ) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, eps growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Creative Medical Technology Holdings Inc (CELZ) Key Strengths (2)
Earnings per share surging 358.90% year-over-year
Trading at 1.15x book value, attractively priced
Supporting Valuation Data
Creative Medical Technology Holdings Inc (CELZ) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 1071.7x annual revenue
Very low institutional interest at 7.57%
Micro-cap company with very limited liquidity and high volatility
Supporting Valuation Data
Creative Medical Technology Holdings Inc (CELZ) Detailed Analysis Report
Overall Assessment
This company scores 26/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 9.0/10) while 5 fall into concern territory (avg 1.4/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on EPS Growth, Price/Book. Valuation metrics including Price/Book (1.15) suggest the stock is attractively priced. Growth metrics are encouraging with EPS Growth at 358.90%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (1071.70) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -98.10%, Operating Margin at -101379.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -98.10% needing improvement to support the investment thesis. Third, growth sustainability, with EPS Growth at 358.90% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
CELZ Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
CELZ's Price-to-Sales ratio of 1071.70x trades 186% above its historical average of 374.16x (84th percentile), historically expensive. The current valuation is 47% below its historical high of 2023.04x set in Mar 2024, and Infinity% above its historical low of 0x in Jan 2020. Over the past 12 months, the PS ratio has expanded from ~721.2x, reflecting growing market expectations outpacing revenue growth.
WallStSmart Analysis Synopsis
Data-driven financial summary for Creative Medical Technology Holdings Inc (CELZ) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Creative Medical Technology Holdings Inc operates as a stable business with moderate growth and solid fundamentals. Revenue reached 6,000 with 0% growth year-over-year. The company is currently unprofitable, posting a 0.0% profit margin.
Key Findings
Spending 9168% of revenue (550,077) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -2M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Volatility is elevated with a beta of 2.15, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Creative Medical Technology Holdings Inc.
Bottom Line
Creative Medical Technology Holdings Inc offers stability with moderate growth and solid fundamentals. The valuation may present an opportunity for patient investors, though limited growth means returns will likely come from dividends and modest capital appreciation rather than explosive gains.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Creative Medical Technology Holdings Inc(CELZ)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
Creative Medical Technology Holdings, Inc., a biotechnology company, focuses on immunology, urology, orthopedics, and neurology using adult stem cell treatments. The company is headquartered in Phoenix, Arizona.